Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994)

European Journal of Cancer

Volumn 41, Issue 3, 2005, Pages 411-415

  Ciatto, Stefano ^a   Gervasi, Ginetta ^a   Bonardi, Rita ^a   Frullini, Paola ^a   Zendron, Paola ^a   Lombardi, Claudio ^b   Crocetti, Emanuele ^a   Zappa, Marco ^a  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^b Torre Galli Hospital   (Italy)

Author keywords

Overdiagnosis; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TIME SERIES ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY;

AGED; COHORT STUDIES; DIAGNOSTIC ERRORS; FEASIBILITY STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHYSICAL EXAMINATION; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 13244283284     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.09.030     Document Type: Article

References (14)

1. The International Prostate Screening Trial Evaluation Group. Rationale for randomised trials of prostate cancer screening. Eur J Cancer 1999, 35, 262-271
2. H.J. de Koning, A. Auvinen, and A. Berenguer-Sanchez Large-scale randomized prostate cancer screening trials; program performance in the ERSPC and PLCO trials Int J Cancer 97 2002 237 244
3. J.M. Legler, E.J. Feuer, and A.L. Potosky The role of prostate specific antigen (PSA) testing pattern in the recent prostate cancer incidence decline in the United States Cancer Cause Control 9 1998 519 527
4. G.S. Cooper, Z. Yuan, and R.N. Jethva Determination of county-level prostate carcinoma incidence and detection rates with Medicare claims data Cancer 92 2001 102 109
5. A. Shibata, and A.S. Whittemore Prostate cancer incidence and mortality in the United States and the United Kingdom J Natl Cancer Inst 93 2001 1109 1110
6. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 8688 8778
7. R. Etzioni, D.F. Penson, and J.M. Legler Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
8. J.L. Stanford, Z. Feng, and A.S. Hamilton Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study JAMA 283 2000 354 360
9. M. Zappa, S. Ciatto, and R. Bonardi Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study Ann Oncol 9 1998 1297 1300
10. S. Ciatto, M. Zappa, and R. Bonardi Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screen Eur J Cancer 36 2000 1347 1350
11. S. Ciatto, R. Bonardi, and A. Mazzotta Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate specific antigen Tumori 81 1995 225 229
12. E. Paci, E. Crocetti, and G. Miccinesi Tuscany cancer registry D.M. Parkin S.L. Whelan J. Ferlay L. Teppo D.B. Thomas Cancer incidence in five continents vol. VIII 2002 IARC Scientific Publications Lyon 362 363 [No. 155]
13. E. Crocetti, S. Ciatto, and M. Zappa Prostate cancer: different incidence but not mortality. Trends within two areas of Tuscany, Italy J Natl Cancer Inst 93 2001 876 877
14. M. Tornblom, H. Eriksson, and S. Franzen Lead time associated with screening for prostate cancer Int J Cancer 108 2004 122 129